Waiv Closes $35 Million in Total Funding with New Investment from CRB Health Tech
Waiv, formerly Owkin Dx, an AI technology company advancing precision testing in oncology, today announced the close of its financing round at $35 million. The Series A round was completed with investment from CRB Digital Health III, a fund managed by CRB Health Tech, Southern Europe’s largest venture capital fund solely dedicated to digital health, and business angels. They join initial investors OTB Ventures and Alpha Intelligence Capital, who co-led the initial round with participation from Serena Data Ventures, Karista, and SistaFund as announced in March 2026.
Ignasi Heras Vila, General Partner, CRB Health Tech:
“Waiv is building one of the most compelling platforms we’ve seen at the intersection of AI and precision oncology. Their ability to extract molecular-grade insights from routine pathology has the potential to redefine how diagnostics are delivered at scale. Our participation in this extension reflects our strong conviction in both the team, led by Meriem Sefta and Lionel Guillou, and the long-term impact of their technology,”
Meriem Sefta, CEO and Co-Founder, Waiv:
“This additional investment sends a strong signal of confidence in what we are building at Waiv. With recent regulatory approvals secured and our platform already deployed in clinical settings, this capital will help us move even faster, expanding our reach to more laboratories, our commercial traction, and ultimately improving oncology and precision medicine care for more patients.”
The announcement follows a significant regulatory milestone shared last week: Waiv secured CE marking under IVDR for two of its AI precision tests: RlapsRisk® BC for breast cancer prognostic risk profiling and MSIntuit® CRC for colorectal cancer MSI screening. Together, these milestones position Waiv to accelerate adoption by laboratories and healthcare providers across Europe and beyond.
About CRB Health Tech
CRB Health Tech is an independent venture capital firm founded in 2008, with offices in Madrid and Barcelona. CRB Digital Health III, its third fund, is the largest fund in Southern Europe solely dedicated to digital health. The fund targets disruptive technologies in prevention, diagnosis, and treatment, as well as platforms that improve the efficiency and sustainability of healthcare systems, focusing on companies with validated business models and clear scalability potential.
For more information, please visit www.crbhealthtech.com
About Waiv
Waiv exists to catalyze precision medicine with clinical-grade, AI-powered tests that accelerate biomarker discovery and detection, outcome prediction, and treatment-response assessment across oncology.
Built on over seven years of validated medical-AI innovation and one of Europe’s largest multi-institutional data networks, Waiv delivers precise, accurate, and fast analyses that support treatment decisions. Waiv collaborates with global pharmaceutical companies, research institutions, diagnostic organizations and healthcare systems to bring scalable precision medicine to patients worldwide.
Waiv is backed by OTB Ventures and Alpha Intelligence Capital (AIC), with participation from Serena Data Ventures, Karista, SistaFund, and CRB Health Tech, with an initial financing of $35 million dollars to expand its clinical testing solutions and fuel commercial expansion.
